Tarlatamab: 7 agencies, 2025–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Every decisive outcome on file for tarlatamab is negative — 3 of them, across 3 agencies.
Every record falls within a 1.2-year window, 9 Apr 2025 to 8 Jul 2026 — a compressed review cycle.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — HAS (France), PHARMAC (New Zealand) and TLV (Sweden) among them — hold no record for tarlatamab at all.
The file is active: 9 of 10 records date from 2023 or later.
5 distinct indication wordings are recorded for tarlatamab by the agencies that label one in English (AWMSG, EU JCA, NICE, PBAC and SMC).
4 of these 10 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
CHUIKYO (Japan) was first to assess tarlatamab, on 9 Apr 2025; EU JCA (EU joint assessment) did not open a file until 8 Jul 2026 — a moderate spread of 1.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 9 dated records fall in 2025 alone.
PBAC (Australia) is the only agency to have returned to tarlatamab, recording 4 separate entries.
7 of the 18 agencies in this archive hold a record for tarlatamab.
The full ledger for tarlatamab reads 3 not recommended, 3 advice, 1 appraised and 1 deferred to NICE, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2026 | Extensive-stage small cell lung cancer (ES-SCLC) | Not Recommended | source |
| SMC (Scotland) | 10 Nov 2025 | Treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including plati… | not recommended | source |
| NICE (England) | 20 Aug 2025 | NICE TA1091 | not recommended | source |
| AWMSG (Wales) | 16 Jul 2025 | For the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or… | excluded, NICE appraised | source |
| CHUIKYO (Japan) | 9 Apr 2025 | イムデトラ: cost-effectiveness evaluation (new product, high price or high sales) | evaluation under way | source |
5 further decisions for tarlatamab, across 3 agencies, are not shown here. They include the most recent record on file, 8 Jul 2026 from EU JCA (EU joint assessment); its outcome is in the subscriber dataset. They link to 2 further source documents.
Related molecules
- pemetrexed — divergent outcome (not recommended vs recommended) on a shared indication
- nivolumab — divergent outcome (not recommended vs recommended) on a shared indication
- bevacizumab — divergent outcome (not recommended vs recommended) on a shared indication
- durvalumab — divergent outcome (not recommended vs recommended) on a shared indication
- crizotinib — divergent outcome (not recommended vs recommended) on a shared indication
- mobocertinib — divergent outcome (not recommended vs withdrawn) on a shared indication
Coverage: 10 decisions for tarlatamab from 7 agencies, 2025 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.